Regulatory cells involved in the suppression of active EAE

调节细胞参与抑制活性 EAE

基本信息

  • 批准号:
    7305609
  • 负责人:
  • 金额:
    $ 7.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-01 至 2009-07-31
  • 项目状态:
    已结题

项目摘要

To study the suppressive mechanism of myelin antigen-specific autoreactive T cells in the periphery, we have generated transgenic (Tg) mice expressing Myelin Basic Protein (MBP)-specific human T cell receptor (TCR) isolated from an MS patient. Since conventional myelin antigen-specific TCR Tg mice were generated from encephalitogenic T cell clones, the Tg mice generated from the encephalitogenic TCR developed spontaneous or active EAE. However, it is impossible to identify encephalitogenic T cell clones from humans. We chose the T cell clone which recognize the immunodominant epitope of MBP, MBP111-129, in humans expressing the HLA-DRB1*0401. Interestingly, CD4+CD25- Tg Tcells can differentiate into Th1 cells in vitro and the Th1 cells induce EAE upon adoptive transfer, while EAE cannot be induced in the MS2-3C8 TCR Tg mice by immunization with MBP111-129/CFA. This preliminary experiment suggests that Tregs capable of suppressing the differentiation of encephalitogenic T cells develop in the MS2-3C8 TCR Tg mice. We found that MHC class II-restricted MBP-specific CD8+ Tg T cells develop together with CD4+ Tg T cells in the MS2-3C8 Tg mice. The CD8+ Tg T cells are cytotoxic and produce a high amount of IFN-? in response to MBP111-129/HLA-DRB1*0401 complexes and exhibit Tc1 phenotype. We also found that 8-12% of CD4+ Tg na?ve T cells express CD4+CD25+ Foxp3+ phenotype in the MS2-3C8 Tg mice and these Tg Tregs suppress the proliferation of CD4+ CD25-Tg T cells. These CD8+ Tg T cells and CD4+CD25+ Tg T cells are candidate Tregs which suppress the induction of active EAE. In this study, we will identify the regulatory T cell subsets which can suppress active EAE and investigate their suppressive potential against EAE induced by other myelin antigens, PLP and MOG. This study could lead to a better understanding of Tregs and their suppressive mechanism and a solid ground for a NIH RO1 application. 1 Principal Investigator/Program Director (Last, First, Middle): Ito, Kouichi
为了研究外周中髓鞘抗原特异性自身反应性T细胞的抑制机制,我们产生了表达从MS患者分离的髓鞘碱性蛋白(MBP)特异性人T细胞受体(TCR)的转基因(Tg)小鼠。由于常规的髓鞘抗原特异性TCR Tg小鼠是由致脑炎性T细胞克隆产生的,因此由致脑炎性TCR产生的Tg小鼠发生自发性或主动性EAE。然而,不可能从人类中鉴定致脑炎性T细胞克隆。我们选择了在表达HLA-DRB 1 *0401的人中识别MBP的免疫显性表位MBP 111 -129的T细胞克隆。有趣的是,CD 4 + CD 25- Tg T细胞可以在体外分化为Th 1细胞,并且Th 1细胞在过继转移后诱导EAE,而用MBP 111 -129/CFA免疫不能在MS 2 - 3C 8 TCR Tg小鼠中诱导EAE。该初步实验表明,在MS 2 - 3C 8 TCR Tg小鼠中产生了能够抑制致脑炎性T细胞分化的TCR 4。我们发现,MHC II类限制性MBP特异性CD 8 + Tg T细胞与CD 4 + Tg T细胞一起在MS 2 - 3C 8 Tg小鼠中发育。CD 8 + Tg T细胞具有细胞毒性,并产生大量的IFN-?对MBP 111 -129/HLA-DRB 1 *0401复合物应答,并表现出Tc 1表型。我们还发现,8-12%的CD 4 + Tg na?在MS 2 - 3C 8 Tg小鼠中,ve T细胞表达CD 4 + CD 25 + Foxp 3+表型,并且这些Tg T细胞抑制CD 4 + CD 25-Tg T细胞的增殖。这些CD 8 + Tg T细胞和CD 4 + CD 25 + Tg T细胞是抑制活性EAE诱导的候选T细胞。在这项研究中,我们将确定调节性T细胞亚群,可以抑制活动性EAE,并探讨其对其他髓鞘抗原,PLP和MOG诱导的EAE的抑制潜力。这项研究可能会导致更好地了解TcR及其抑制机制,并为NIH RO 1的应用奠定坚实的基础。1名主要研究者/项目负责人(最后,第一,中间):Ito,Kouichi

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KOUICHI ITO其他文献

KOUICHI ITO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KOUICHI ITO', 18)}}的其他基金

Human Keratin (K14)-MBP/MBP-TCR Transgenic Animal Model
人角蛋白(K14)-MBP/MBP-TCR转基因动物模型
  • 批准号:
    7640789
  • 财政年份:
    2008
  • 资助金额:
    $ 7.8万
  • 项目类别:
Human Keratin (K14)-MBP/MBP-TCR Transgenic Animal Model
人角蛋白(K14)-MBP/MBP-TCR转基因动物模型
  • 批准号:
    7385532
  • 财政年份:
    2008
  • 资助金额:
    $ 7.8万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 7.8万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 7.8万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 7.8万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 7.8万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 7.8万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 7.8万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 7.8万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 7.8万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 7.8万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 7.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了